Hoth Therapeutics Inc. (HOTH) Begins First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa

April 22, 2021 9:03 AM EDT
Get Alerts HOTH Hot Sheet
Price: $1.48 -1.33%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.

"We are excited to have reached this pivotal milestone in our BioLexa development program," stated Robb Knie, CEO of Hoth Therapeutics. "There continues to be an unmet need for improved therapeutics for patients suffering from mild to moderate eczema. The BioLexa clinical trial brings us one step closer to potentially improve the quality of life for those who need this novel therapeutic."

Hoth is conducting the BioLexa clinical trial in Australia. Additional information and updates on the BioLexa clinical trial can be found by visiting and ClinicalTrials.Gov.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments